TriangleNCT00869206 · OUTCOME
Bone Turnover Assessed by Serum C-telopeptide (CTX) Levels (Prostate Cancer)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- COUNT_OF_PARTICIPANTS
- Unit
- Participants
- Interval / dispersion
- Not reported
- Time frame
- from baseline up to 24 months
What was measured
To compare the suppression of serum markers of bone resorption of patients with metastatic breast cancer, metastatic prostate cancer, or myeloma involving bone receiving every 12 week dosing of zoledronic acid to those receiving every 4 week dosing. The number of patients with high \& low CTX values by arm will be reported here.
Analysis population: 207 prostate cancer patients who were treated and included in this portion of the substudy.
Groups in this outcome
Prostate Cancer 4 Weeks
Patients with Prostate Cancer receive zoledronic acid IV over at least 15 minutes every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
Prostate Cancer 12 Weeks
Patients with Prostate Cancer receive zoledronic acid IV over at least 15 minutes every 12 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
| Group | Source count |
|---|---|
| Prostate Cancer 4 Weeks | 104 |
| Prostate Cancer 12 Weeks | 103 |
Reported measurements
Low CTX (<0.415ng/ml)
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Prostate Cancer 4 Weeks | 34 | Not reported | Not reported | Not reported | Not reported |
| Prostate Cancer 12 Weeks | 49 | Not reported | Not reported | Not reported | Not reported |
High CTX (>.0.415ng/ml)
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Prostate Cancer 4 Weeks | 70 | Not reported | Not reported | Not reported | Not reported |
| Prostate Cancer 12 Weeks | 54 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 34
- group Id
- OG001
- value
- 49
- title
- Low CTX (<0.415ng/ml)
- categories
- measurements
- group Id
- OG000
- value
- 70
- group Id
- OG001
- value
- 54
- title
- High CTX (>.0.415ng/ml)
- denoms
- counts
- group Id
- OG000
- value
- 104
- group Id
- OG001
- value
- 103
- units
- Participants
- description
- To compare the suppression of serum markers of bone resorption of patients with metastatic breast cancer, metastatic prostate cancer, or myeloma involving bone receiving every 12 week dosing of zoledronic acid to those receiving every 4 week dosing. The number of patients with high \& low CTX values by arm will be reported here.
- groups
- description
- Patients with Prostate Cancer receive zoledronic acid IV over at least 15 minutes every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
- id
- OG000
- title
- Prostate Cancer 4 Weeks
- description
- Patients with Prostate Cancer receive zoledronic acid IV over at least 15 minutes every 12 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
- id
- OG001
- title
- Prostate Cancer 12 Weeks
- param Type
- COUNT_OF_PARTICIPANTS
- population Description
- 207 prostate cancer patients who were treated and included in this portion of the substudy.
- reporting Status
- POSTED
- time Frame
- from baseline up to 24 months
- title
- Bone Turnover Assessed by Serum C-telopeptide (CTX) Levels (Prostate Cancer)
- type
- SECONDARY
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice